You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.
The company, formerly known as Klaris Diagnostics, plans to use the funding to work toward US FDA clearance of its clinical microbiology diagnostics platform.
The DeepChek-HIV assays are designed for settings running either Sanger sequencing or next-generation sequencing workflows, according to the company.
MinIon sequencing identified pathogens and antimicrobial resistance genes in the gut of preterm infants with suspected necrotizing enterocolitis.
Hardy Diagnostics has partnered with NG Biotech to exclusively distribute the 15-minute test in the US. It has also brought it through the US regulatory process.
According to Natera CEO Steve Chapman, the agreement will not detract from Natera's own efforts to establish its exome sequencing-based Signatera assay.
The company said its test is faster, more precise, and cheaper than the current gold standard Cepheid GeneXpert test.
The test could potentially enable labs to bring resistance testing in house, rather than send testing out to Canada's National Microbiology Laboratory.
The project, called Seq&Treat, will be implemented in Brazil, China, Georgia, India, and South Africa starting in October.
The closure has no impact on the firm's other Los Gatos location, the original home of GeneWeave Biosciences, which Roche acquired in 2015 for up to $425 million.